Experienced in Chronic Spontaneous Urticaria (CSU)

Dr. Jill Waibel

Dermatology
Miami Dermatology And Laster Institute
3683 S Miami Ave Ste 200, 
Miami, FL 
Offers Telehealth
Experienced in Chronic Spontaneous Urticaria (CSU)
Miami Dermatology And Laster Institute
3683 S Miami Ave Ste 200, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jill Waibel is a Dermatologist in Miami, Florida. Dr. Waibel is rated as an Experienced provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). Her top areas of expertise are Hypomelanotic Disorder, Dyschromatosis Universalis Hereditaria, Dyschromatosis Symmetrica Hereditaria, and Griscelli Syndrome.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Chronic Spontaneous Urticaria (CSU).

Specialties
Dermatology
Licenses
Dermatology in OH
Hospital Affiliations
South Miami Hospital
Baptist Hospital Of Miami
Geisinger Medical Center
Doctors Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 29 Less Insurance Carriers -

Locations

Miami Dermatology and Laster Institute
3683 S Miami Ave Ste 200, Miami, FL 33133

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Device
Study Phase: Not Applicable
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring
The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Device
Study Phase: Not Applicable
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring With an Optimized Post-Procedure Treatment Plan
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring With an Optimized Post-Procedure Treatment Plan
Enrollment Status: Unknown
Publish Date: March 06, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 13 Less Clinical Trials

59 Total Publications

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
Similar Doctors
Distinguished in Chronic Spontaneous Urticaria (CSU)
Dr. Gil Yosipovitch
Dermatology
Distinguished in Chronic Spontaneous Urticaria (CSU)
Dr. Gil Yosipovitch
Dermatology

Dr Jane Asprinio O'Brien PA

1295 NW 14th St, 
Miami, FL 
 (9.7 miles away)
305-243-6704
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gil Yosipovitch is a Dermatologist in Miami, Florida. Dr. Yosipovitch is rated as an Elite provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). His top areas of expertise are Prurigo Nodularis, Atopic Dermatitis, Stasis Dermatitis and Ulcers, and Lichen Simplex Chronicus.

Advanced in Chronic Spontaneous Urticaria (CSU)
Dr. Francisco Flores
Dermatology
Advanced in Chronic Spontaneous Urticaria (CSU)
Dr. Francisco Flores
Dermatology

The Derm Group LLP

14601 SW 29th St Ste 206, 
Miramar, FL 
 (20.2 miles away)
954-885-5551
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francisco Flores is a Dermatologist in Miramar, Florida. Dr. Flores is rated as a Distinguished provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). His top areas of expertise are Epidural Lipomatosis, Contact Dermatitis, Melasma, and Membranous Nephropathy.

Advanced in Chronic Spontaneous Urticaria (CSU)
Dr. David Rodriguez
Dermatology
Advanced in Chronic Spontaneous Urticaria (CSU)
Dr. David Rodriguez
Dermatology

Rashmi Unwala MD PA

8370 W Flagler St Ste 200, 
Miami, FL 
 (4.8 miles away)
305-225-0400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Rodriguez is a Dermatologist in Miami, Florida. Dr. Rodriguez is rated as a Distinguished provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). His top areas of expertise are Rosacea, Melasma, Membranous Nephropathy, and Epidermodysplasia Verruciformis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waibel's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile